相关实验视频

Updated: May 7, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

发现了高亲和度的SMARCA2/4原体配体,并开发了强大且特别选择性的SMARCA2 PROTAC降解剂

Lingying Leng¹, Wenbin Tu^1,2, Lin Yang¹

¹Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.

Journal of medicinal chemistry

|January 2, 2025

概括

针对SMARCA2蛋白降解是一种新的癌症治疗策略. 这项研究开发了新的配体和PROTAC降解剂,发现了强大的SMARCA2和SMARCA2/4降解剂用于癌症治疗.

科学领域:

分子生物学分子生物学
生物化学生物化学
癌症治疗方法癌症治疗方法

背景情况:

这种SWI/SNF染色体重塑复合物涉及相互排斥的催化ATPase子单元SMARCA2和SMARCA4.
这些子单元表现出合成-致死关系,使SMARCA2成为突变SMARCA4癌症的潜在治疗点.
针对SMARCA2进行降解,为特定的人类癌症提供了一个新的治疗策略.

研究的目的:

设计,合成和生物评估针对SMARCA2/4.4的新型配体.
开发使用高亲和度SMARCA连接体和VHL-1连接体的蛋白质溶解向金马 (PROTAC) 降解剂.
为了确定SMARCA2和SMARCA2/4蛋白质的强效和选择性降解剂.

主要方法:

新型SMARCA2/4配体的设计和合成.
通过将SMARCA配体与VHL-1配体结合,开发PROTAC分子.
对合成化合物的生物评估,以检测其降解活性.
基基因连接体亲和力和降解剂功率和选择性的表征.

主要成果:

发现了高亲和度的SMARCA2/4原体连接体.
成功开发了一种强效和选择性的SMARCA2降解剂.
识别一种非常强大的SMARCA2/4和PBRM1降解剂.
在SWI/SNF复合体中展示PROTAC技术用于向蛋白质降解.

结论:

新的SMARCA2/4配体和PROTAC降解剂成功设计和合成.
开发的降解剂对SMARCA2和SMARCA2/4.4具有强大和选择性的活性.
这项研究验证了SMARCA2降解作为SMARCA4突变癌症的可行治疗策略.
这些发现为新的向癌症治疗铺平了道路.

更多相关视频

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...